Skip to main content
ASTRO 2024 Main banner
Icon Legend
Presentation Icons
Event Add-on
Event Add-on
In Person Only
In Person Only
Off-site Event
Off-site Event
Location: Marriott Marquis
Location: Marriott Marquis
Back
Evaluation Watch onDemand

Lung Cancer/Thoracic Malignancies
Session Type: Scientific

SS 16 - Lung 3: Clinical Trials of Chemoradioimmunotherapy and Risk Adapted Radiotherapy for Advanced Lung Cancer

Monday, September 30, 2024
10:45 AM – 12:00 PM ET
Location: Room 207

AMA PRA Category 1 Credits 1.25

CAMPEP Credits: 1.25

MDCB Credits: 1.25

Presentations:

  • 10:45 AM – 10:55 AM ET
    Phase II Trial of Concurrent Durvalumab and Radiation Therapy for Locally Advanced Lung Cancer

    Presenter: Emily Lebow, MD – University of Pennsylvania

  • 10:55 AM – 11:05 AM ET
    Hypofractionated Radiotherapy plus Concurrent Chemotherapy with or without Consolidation Immunotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer (GASTO-1052)

    Presenter: Hui Liu, MD, PhD – Sun Yat-Sen University Cancer Center

  • 11:05 AM – 11:15 AM ET
    The Selective Personalized RadioImmunotherapy for Locally Advanced NSCLC Trial (SPRINT): Patient-Reported Outcomes

    Presenter: Nitin Ohri, MD, MS – Montefiore Einstein Comprehensive Cancer Center

  • 11:15 AM – 11:25 AM ET
    Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer: FLARE-RT Mature Outcomes and Patterns of Failure

    Presenter: Sunan Cui, PhD – University of Washington

  • 11:25 AM – 11:35 AM ET
    A Phase 2 Single-Arm Trial of High-Dose Radiotherapy Added to Immunotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

    Presenter: Nikhil Kotha, MD – Stanford Radiation Oncology

  • 11:35 AM – 11:45 AM ET
    Durvalumab Combined with Concurrent Chemoradiotherapy in Patients with Limited-Stage Small-Cell Lung Cancer: A Prospective, Single-Arm, Phase II Clinical Trial

    Presenter: Wen Bin Shen, MD – The Fourth Hospital of Hebei Medical University

  • 11:45 AM – 11:55 AM ET
    Simultaneous Integrated Boost vs. Conventional Radiotherapy for Patients with Limited-Stage Small Cell Lung Cancer: A Randomized, Non-Inferiority, Open-Label, Phase 3 Trial

    Presenter: Tianyou Zhan, MD – National Cancer Center/National Clinical Research Center for Cancer Cancer Hospital, CAMS & PUMC